The US Food and Drug Administration has approved Eli Lilly’s once-weekly basal insulin, Onswik, for adults with type ​2 ...

People with type 2 diabetes who take insulin can switch from daily basal insulin injections to weekly injections of Onswik ...

The FDA has approved the once-weekly injectable basal insulin drug insulin efsitora alfa-gobe (Onswik, Eli Lilly) for use as ...

The FDA approval is the fourth global approval for Onswik in adults with type 2 diabetes, following regulatory actions by the ...

Eli Lilly (LLY) said Thursday the US Food and Drug Administration approved its once-weekly Onswik basal insulin injection treatment to control high blood sugar in adults with type ...

Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora ...

The FDA approved Onswik, a once-weekly basal insulin for adults with type 2 diabetes. Here's how it works, who it's for and ...

Daily injections become once a week. For those continuing diabetes treatment, this is a change that affects daily life ...

Eli Lilly has won U.S. Food and Drug Administration approval for Onswik, a once-weekly basal insulin injection treatment for adults with type 2 diabetes. Eli Lilly on Thursday said Onswik is designed ...

The US Food and Drug Administration has officially approved Eli Lilly’s once-weekly basal insulin for adults with type 2 diabetes- a move that offers patients an alternative to ...

Lilly's new once-weekly insulin, Onswik (insulin efsitora alfa-gobe), recently received FDA approval, marking a significant milestone in the diabetes care and treatment.

Adults with type 2 diabetes will have a new alternative to daily insulin injections now that the U.S. Food and Drug Administration (FDA) approved a new once-a-week insulin injection.